At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
non-interventionalother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting
In Brief
An observational study evaluating non-interventional for Non-Alcoholic Fatty Liver Disease. Completed, enrolled 50 participants across 1 site.
Detailed Summary
This study aims to measure the effect of GLP-1 analogues on non-alcoholic fatty liver disease in patients with diabetes and/or obesity in a clinical context. Previous studies showed a positive effect of this medication, but these studies always took place in highly controlled settings. The question is to what extent liver values evolve in a non-controlled context. The real effect and thus the clinical utility of GLP-1 analogues will be measured.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Alcoholic Fatty Liver Disease
CountriesBelgium
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartOct 2023
Primary CompletionOct 2023
Study CompletionMay 2025
First PostedJun 2025
TodayJul 2026
First PostedJun 15, 2025
Enrollment StartOct 9, 2023
Primary CompletionOct 26, 2023
Study CompletionMay 12, 2025
TodayJul 2, 2026
Enrollment to primary: 17 daysPosted 1.0 years ago
Interventions
non-interventionalother
non-interventional